Baird Medical Investment Holdings Ltd.

Baird Medical Investment Holdings Ltd. is a medical technology company established in 2012 and headquartered in Guangzhou, China. The company specializes in the research, development, manufacturing, and sale of minimally invasive medical devices, with a core focus on Microwave Ablation (MWA) technology. Its mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions, aiming to develop intelligent systems that guide diagnostic decisions and preventive healthcare strategies.

Baird Medical's key products include microwave ablation apparatus and needles designed for the treatment of various benign and malignant tumors. These devices are applied across multiple market segments, including thyroid nodules, liver cancer, lung cancer, breast lumps, bone lesions, and uterine fibroids. The company operates on a "razor-and-blade" business model, selling MWA generators and generating recurring revenue from high-margin disposable needles. Baird Medical is recognized as a market leader in China for thyroid microwave ablation devices and consumables and is actively expanding its international presence.

Haimei Wu serves as the Chief Executive Officer and Chairwoman of Baird Medical. In December 2025, Mark Saxton was appointed U.S. CEO to spearhead market expansion efforts in the United States. Recent notable developments include the establishment of a U.S. manufacturing base in partnership with MPS Medical in December 2025, signifying a strategic shift towards becoming a global medical technology enterprise. The company has also expanded its global footprint with regulatory clearances in Argentina, entry into the Egyptian market, and successful liver tumor ablation procedures in Bangladesh in late 2025 and early 2026. Baird Medical actively participates in industry events, such as the NASIT 2026, to accelerate its U.S. expansion and promote its FDA 510(k)-certified MWA platforms, which are currently utilized in over 30 U.S. hospitals and clinics.